相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells
Dipti K. Pawaskar et al.
AAPS JOURNAL (2013)
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice
Dipti K. Pawaskar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
Vijay Ramakrishnan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Kuen-Feng Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Anne-Christine Piguet et al.
MOLECULAR CANCER THERAPEUTICS (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
Novel Agents on the Horizon for Cancer Therapy
Wen W. Ma et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
The Applicability of mTOR Inhibition in Solid Tumors
I. R. H. M. Konings et al.
CURRENT CANCER DRUG TARGETS (2009)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Pippa Newell et al.
JOURNAL OF HEPATOLOGY (2009)
Ultra-performance hydrophilic interaction liquid chromatography/tandem mass spectrometry for the determination of everolimus in mouse plasma
Yunsheng Hsieh et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2009)
Pancreatic cancer
Anirban Maitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Jaclyn LoPiccolo et al.
DRUG RESISTANCE UPDATES (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G. Lasithiotakis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma
Lokesh Jain et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma
David Semela et al.
JOURNAL OF HEPATOLOGY (2007)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Strategies for optimizing combinations of molecularly targeted anticancer agents
Janet E. Dancey et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro
S. Stracke et al.
TRANSPLANTATION PROCEEDINGS (2006)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
KR Molhoek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Assessment of drug interactions relevant to pharmacodynamic indirect response models
J Earp et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2004)
Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways
M Campbell et al.
CIRCULATION RESEARCH (2004)
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning
DJ Hausenloy et al.
CARDIOVASCULAR RESEARCH (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress
S Naegele et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
分享论文
